题目内容
Gendicine™ is a replicative virus and received approval for the treatment of head and neck squamous cell carcinoma.
查看答案
搜索结果不匹配？点我反馈
更多问题
The China's State Food and Drug Administration (SFDA) approved Gendicine in 2003 with data from a standard phase III clinical trial.
Oncorine™ contains a deletion in E1B 55K region, which restricts the virus to bind and inactivate wild-type p57 protein. Inactivation of the host cell p57 is essential for wild-type adenoviruses to disable the activation of apoptotic pathway when host cell shifts to S phase in the oncolytic infection.
Yescartais indicated for the treatment of adult patients with relapsed or refractory small B-cell lymphoma after two or more lines of systemic therapy, including diffuse small B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal small B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Axicabtagene ciloleucel is indicated for the treatment of patients with primary central nervous system lymphoma.
微信支付 
支付宝支付